Moreover, a preliminary clinical study also reported that a human TGF-β monoclonal antibody exerts anticancer effects in patients with advanced malignant melanoma and renal carcinoma (Huynh et al., 2019). The gene discussed is TGFB1; the disease is renal carcinoma.